Market capitalization | $39.56m |
Enterprise Value | $23.26m |
P/E (TTM) P/E ratio | 0.11 |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 12.78 |
P/S ratio (TTM) P/S ratio | 21.74 |
P/B ratio (TTM) P/B ratio | 0.05 |
Revenue growth (TTM) Revenue growth | 7.06% |
Revenue (TTM) Revenue | $1.82m |
As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.
Sep '24 |
+/-
%
|
||
Revenue | 1.82 1.82 |
7%
7%
|
|
Gross Profit | 0.40 0.40 |
37%
37%
|
|
EBITDA | 6.36 6.36 |
147%
147%
|
EBIT (Operating Income) EBIT | 6.20 6.20 |
145%
145%
|
Net Profit | 5.80 5.80 |
141%
141%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
China Sxt Pharmaceuticals, Inc. is a holding company, which engages in the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces (TCMP). Its product categories includes directly-oral, after-soaking-oral, fine, and regular TCMP. It distributes its product under the Suxuantang brand. The company was founded by Feng Zhou in 2005 and is headquartered in Taizhou, China.
Head office | Virgin Islands, British |
CEO | Sze Zhou |
Employees | 75 |
Founded | 2005 |
Website | www.sxtchina.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.